Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Land & Improvements (2018 - 2020)

Historic Land & Improvements for ImmunoTech (AIM) over the last 3 years, with Q3 2020 value amounting to $10.5 million.

  • ImmunoTech's Land & Improvements changed N/A to $10.5 million in Q3 2020 from the same period last year, while for Sep 2020 it was $10.5 million, marking a year-over-year change of. This contributed to the annual value of $10.5 million for FY2019, which is 0.0% changed from last year.
  • As of Q3 2020, ImmunoTech's Land & Improvements stood at $10.5 million.
  • ImmunoTech's 5-year Land & Improvements high stood at $10.5 million for Q4 2018, and its period low was $10.5 million during Q4 2018.
  • In the last 3 years, ImmunoTech's Land & Improvements had a median value of $10.5 million in 2018 and averaged $10.5 million.
  • Within the past 5 years, the most significant YoY rise in ImmunoTech's Land & Improvements was 0.0% (2019), while the steepest drop was 0.0% (2019).
  • ImmunoTech's Land & Improvements (Quarter) stood at $10.5 million in 2018, then changed by 0.0% to $10.5 million in 2019, then changed by 0.0% to $10.5 million in 2020.
  • Its Land & Improvements was $10.5 million in Q3 2020, compared to $10.5 million in Q2 2020 and $10.5 million in Q1 2020.